Actively Recruiting
Evaluating Letermovir Pharmacokinetics and Safety in Children Under 18 and Under 40 kg After Kidney Transplant
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-30
40
Participants Needed
22
Research Sites
5 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ways to prevent cytomegalovirus CMV infection in children and adolescents who have received a kidney transplant and weigh less than 40 kilograms. This trial focuses on understanding how the drug letermovir behaves in the body over time and assessing its safety and tolerance in this young population. The study is a phase 1, open-label, single-arm trial sponsored by Merck Sharp & Dohme LLC. Participants who are between 4 and 52 weeks post-kidney transplant will receive oral letermovir, either as tablets or pellets, or via gastrostomy or nasogastric tube pellets only for 7 consecutive days. The study uses weight-banded dosing to tailor the treatment to each child or adolescents weight. During the study, participants will be closely monitored with blood sampling to measure letermovir levels over a 24-hour period on Day 7. Researchers will also track any adverse events for up to 21 days and note if any participant stops the treatment due to side effects within 7 days. The total study duration for each participant includes the treatment period and safety monitoring, extending until the primary outcome data is collected.
CONDITIONS
Brief Title
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here